Cytokinetics (CYTK) Income Statement

Click line-items for a historical chart and %

Research and development revenues from related parties	5.57M
Research and development, grant and other revenues	441K
License revenues from related parties	53.03M
Total revenues	59.05M
Research and development	19.34M
General and administrative	7.22M
Restructuring charges
Total operating expenses
Operating loss	32.49M
Interest and other, net	111K
Loss before income taxes
Income tax benefit	0
Net loss	31.89M
Deemed dividend related to beneficial conversion feature of convertible preferred stock
Net loss allocable to common stockholders
Net loss per share allocable to common stockholders - basic and diluted
Weighted-average number of shares used in computing net loss per share allocable to common stockholders - basic and diluted

Entities mentioned with CYTK

View All Entities